A part of Watch Media

MedWatchSaturday28 January 2023

  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Search
  • Log in
  • Latest
  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
12/05/2022at 07:30

Genmab beats Q1 expectations and narrows full-year guidance range

The Danish biotech company had a strong first quarter and has increased its minimum revenue guidance for 2022.
Photo: Joost Melis / Genmab / PR
by andreas lønstrup, translated by catherine brett

Genmab ended Q1, 2022 with a revenue of DKK 2.1bn (USD 300m) compared to DKK 1.6bn (USD 230m) for the same period last year. The biotech company also reported an EBIT (earnings before interest and taxes) result of DKK 514m (USD 72.7m) compared to DKK 532m (USD 75m) for Q1, 2021.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters

Get full access for you and your coworkers

Start a free company trial today

Related articles:

  • Photo: Tuala Hjarnø / Genmab / PR

    Genmab enters agreement on cancer biomarker

    For subscribers

  • Photo: Tuala Hjarnø / Genmab / PR

    One day a month, Genmab employees are free to do as they please

    For subscribers

  • Photo: Joost Melis / Genmab / PR

    Cancer drug hope raises Genmab's spirits after legal defeat

    For subscribers

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Foto: Rob Acket/ema
Regulation

CHMP recommends four drugs in January

Bristol Myers Squibb’s Sotyktu, a treatment for moderate-to-severe psoriasis in adults, has gained the favor of the EMA’s expert committee, alongside three generics.
  • CHMP recommends expanded approval of Dupixent
  • Denmark rejects Janssen and Genmab drug twice in January

For subscribers

Klaus Holse is chairman of the Confederation of Danish Industry and board member of at tech firm Terma – both roles with ties to William Demant Invest CEO Niels Jacobsen | Foto: Pr / Dansk Industri
Hearing health

Proposed GN board member has ties to William Demant Invest CEO – GN dismisses connection

For subscribers

Maiken Riise Andersen, ALK's new head of communications and media relations | Foto: Jørgen True, Studie-e
Pharma & biotech

New ALK head of communications to draw in new hires

For subscribers

Foto: GN Store Nord / PR
Hearing health

Analyst: Chairman exit increases chance of GN-Demant merger

For subscribers

Foto: MedWatch
Other

Top news from MedWatch this week

EMA's hovedkvarter i Amsterdam. | Foto: Rob Acket/ema
Pharma & biotech

EMA says antibiotic shortage situation isn't "major event"

For subscribers

Further reading

Foto: Pr/gn
Hearing health

GN could be potential acquisition target, says bank

Danske Bank’s share price target for GN Group leaves a lot stock potential.

For subscribers

Foto: Saniona / PR
Pharma & biotech

Embattled Y-mabs tightens pipeline focus, reduces staff by 35%

After European and American regulatory authorities have left the biotech company in the cold, Y-mabs downsizes both its pipeline and workforce.

For subscribers

Foto: Pr/dnb
Pharma & biotech

DNB Markets recommends to sell Genmab stock

The Norwegian investment bank also lowers its share price target for the Danish biotech company, arguing that analysts are overestimating 2023 sales expectations.

For subscribers

Latest news

  • Top news from MedWatch this week – 27 Jan
  • CHMP recommends four drugs in January – 27 Jan
  • Denmark rejects Janssen and Genmab drug twice in January – 27 Jan
  • New ALK head of communications to draw in new hires – 27 Jan
  • CHMP recommends expanded approval of Dupixent – 27 Jan
  • Proposed GN board member has ties to William Demant Invest CEO – GN dismisses connection – 27 Jan
  • EMA says antibiotic shortage situation isn't "major event" – 27 Jan
  • Analyst: Chairman exit increases chance of GN-Demant merger – 27 Jan
  • AGC Biologics to produce Eli Lilly-developed drug delaying type 1 diabetes – 26 Jan
  • Per Wold-Olsen's retirement is "a great loss for GN" – 26 Jan
See all

Jobs

  • Senior Regulatory Affairs Professional

  • Application Manager

  • Experienced Patent Counsel

  • Head of Regulatory Affairs Danmark

  • Clinical Operational Associate

  • Sr. Director, Drug Safety Physician

  • Specialist for the supply of pharmaceuticals to Danish hospitals

  • Head of International Sales

  • Two department leaders for the Department of Pharmacy and the Department of Drug Design and Pharmacology

  • Commercial Director

  • Application Manager

  • Principal Laboratory Technologist

  • Lead Data Architect

See all jobs

Jobs

  • Senior Regulatory Affairs Professional

  • Application Manager

  • Experienced Patent Counsel

  • Head of Regulatory Affairs Danmark

  • Clinical Operational Associate

  • Sr. Director, Drug Safety Physician

  • Specialist for the supply of pharmaceuticals to Danish hospitals

  • Head of International Sales

  • Two department leaders for the Department of Pharmacy and the Department of Drug Design and Pharmacology

  • Commercial Director

  • Application Manager

  • Principal Laboratory Technologist

  • Lead Data Architect

See all jobs

Colophon

MedWatch
Search

Sections

  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Sitemap
  • RSS feeds

Editor

Mikkel Aabenhus Hemmingsen

mah@medwatch.dk

Tel.: +45 3330 8387

Editor-in-chief

Anders Heering

Publisher

JP/Politiken Media Group Ltd

Advertising

annoncering@infowatch.dk

Tel.: +45 7077 7441

Advertising

Job Advertising

job@infowatch.dk

Tel.: +45 7077 7441

Jobs

Subscription

Try MedWatch or get an offer for a subscription meeting the exact needs of you or your company.

medwatch@infowatch.dk

Tel.: +45 7077 7441

Learn more about subscriptions here

Address

MedWatch

Rådhuspladsen 37

1785 Copenhagen K, Denmark

Tel.: +45 3330 8370

Guidelines

  • Privacy Policy

Copyright © MedWatch — All rights reserved

Microsoft is in the process of discontinuing Internet Explorer – and so are we.
For a better experience, we recommend using one of the following browsers.

Kind regards,
MedWatch

Google ChromeMozilla FirefoxMicrosoft Edge